Breast Cancer, Cancer, Colon Cancer, Malignant Lymphoma
Conditions
Keywords
normoglycemia, cancer, chemotherapy, Hyperglycemia Drug Induced
Brief summary
To assess chemotherapy related hyperglycemia in non-diabetic patients, the investigators will assess the incidence of hyperglycemia and analyze co-medications and risk factors.
Interventions
DRUGChemotherapy
Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
Sponsors
SMG-SNU Boramae Medical Center
National Cancer Center, Korea
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, CHOP regimen) * Patients without history of diabetes mellitus * Normal glucose tolerance, as defined in the protocol
Exclusion criteria
* Patients with diabetes mellitus or hyperglycemia, as defined in the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of type 2 diabetes mellitus | during chemotherapy (about 1 year) | Percentage of patients who progressed to type 2 diabetes |
Secondary
| Measure | Time frame |
|---|---|
| Change in HbA1c | during chemotherapy (about 1 year) |
| Change in glycated albumin | during chemotherapy (about 1 year) |
| Recurrence free survival (RFS) | from the Date of enrollment to the date of disease recurrence or date of any cause assessed upto 100 months |
Countries
South Korea
Contacts
Primary ContactSu Jeong Go
Outcome results
None listed